Johnson & Johnson - AI Stock Analysis

Analysis generated November 25, 2025

Johnson & Johnson (J&J) is a multinational corporation with interests in pharmaceuticals, medical devices, and consumer health products. Founded in 1886, J&J has a robust global presence, providing a diverse range of healthcare solutions. The company's operations are segmented into three main divisions: Pharmaceutical, Medical Devices, and Consumer Health.

J&J boasts a long history of strong financial performance, innovative products, and a commitment to health and wellness. The company's diverse portfolio and broad market reach offer a buffer against economic downturns, making it a relatively stable investment option.

Fundamental Analysis

Johnson & Johnson reported revenue of $24 billion in the last quarter. Compared to the previous quarter, this is an increase of 1.05%, indicative of steady growth. More impressively, the year-over-year revenue growth stands at 6.77%, signaling that J&J is successfully expanding its market reach and product lines.

The net income for the last quarter came in at $5.15 billion, marking a 6.95% decrease compared to the previous quarter. Despite this, the year-over-year net income growth is a striking 91.24%, suggesting that the company has managed to improve its profitability significantly over the last year.

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) for the last quarter was reported at $7.51 billion. This figure represents a 14.08% decrease compared to the previous quarter, which could point to some operational inefficiencies or increased costs. However, with a year-over-year growth of 39.69%, the overall outlook remains positive.

The current P/E (Price to Earnings) ratio for J&J is 19.68, which is within a normal range. This suggests that the stock is neither undervalued nor overvalued, making it an attractive option for investors looking for steadiness.

Technical Analysis

The current stock price for Johnson & Johnson is $206.67, experiencing an increase of 8.55% compared to a month ago. This indicates a positive short-term trend. Over the longer term, the stock price has risen by 36.97% compared to a year ago, further validating a bullish trend.

The Simple Moving Average (SMA10) currently stands at $202.55, up from the previous SMA10 of $201.48. This slight upward movement suggests potential upward price action.

The Relative Strength Index (RSI) is at a low 15.4, indicating that the stock may be oversold and due for a bullish correction. This presents a potential buying opportunity for investors looking to capitalize on a low RSI.

Alternative Data Analysis

Job postings at Johnson & Johnson have decreased by 74% in the last couple of months, with the company currently having 398 open positions. This cutback suggests that J&J may be focusing on improving margins or optimizing costs, a common strategy for maintaining profitability.

The company’s business outlook among employees is neutral, indicating neither overwhelming optimism nor significant pessimism.

In terms of customer acquisition, J&J has seen a 23% increase in web page visitors, reaching an estimated 2.7 million. This uptick is a bullish sign as it suggests increased interest and potential customer growth.

Customer engagement metrics show mixed results. On Instagram, the follower count has grown by 5% to 110,000 followers, indicating rising interest. On Twitter, however, the follower count remains stagnant at 240,000, suggesting a possible plateau in customer engagement on that platform.

According to AltIndex's AI score, which aggregates various data analyses, Johnson & Johnson has a score of 66. This is categorized as a buy signal, further supporting a positive outlook.

Conclusion and Recommendation

Johnson & Johnson presents a mixed yet generally positive investment profile. The company demonstrates solid revenue and net income growth on a year-over-year basis, coupled with a reasonable P/E ratio. The technical indicators confirm a bullish trend, making the current stock price relatively attractive. However, the recent decline in job postings and stagnant Twitter engagement metrics warrant cautious optimism.

Overall, the combination of consistent revenue and income growth, a favorable investor sentiment backed by AltIndex's buy signal, and bullish technical indicators make Johnson & Johnson a stock worth considering for potential investors. As always, investors are advised to perform their own due diligence before making any investment decisions.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.